Compare PRAX & ENVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRAX | ENVA |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 5.8B |
| IPO Year | 2020 | 2011 |
| Metric | PRAX | ENVA |
|---|---|---|
| Price | $364.58 | $237.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 7 |
| Target Price | ★ $572.13 | $185.71 |
| AVG Volume (30 Days) | ★ 401.0K | 302.5K |
| Earning Date | 05-08-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.05 |
| EPS | N/A | ★ 7.45 |
| Revenue | N/A | ★ $3,151,653,000.00 |
| Revenue This Year | N/A | $149.64 |
| Revenue Next Year | $7,758.26 | $16.42 |
| P/E Ratio | ★ N/A | $34.14 |
| Revenue Growth | N/A | ★ 18.58 |
| 52 Week Low | $37.25 | $103.02 |
| 52 Week High | $392.45 | $267.45 |
| Indicator | PRAX | ENVA |
|---|---|---|
| Relative Strength Index (RSI) | 58.43 | 44.18 |
| Support Level | $291.44 | $217.38 |
| Resistance Level | N/A | $246.38 |
| Average True Range (ATR) | 19.51 | 7.77 |
| MACD | 2.70 | -2.57 |
| Stochastic Oscillator | 76.31 | 19.40 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Enova International Inc provides online financial services, including short-term consumer loans, line of credit accounts, and installment loans to customers mainly in the United States and Brazil. Consumers apply for credit online, the company's technology platforms process the applications, and transactions are completed quickly and efficiently. Its customers are predominantly retail consumers and small businesses. Enova markets its financing products under the names CashNetUSA, NetCredit, OnDeck, Headway Capital, and Simplic. The company also operates a money transfer platform under the name Pangea. Geographically, the company generates a majority of its revenue from its business in the United States and the rest from other international countries.